Pathogenesis of Organ Damage in Fabry Disease: The AGALopathy Pathogenetic Pathway.
作者信息
Rozenfeld Paula, Feriozzi Sandro
机构信息
Facultad de Ciencias Exactas, Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), UNLP, CONICET, asociado CIC PBA, La Plata, Argentina.
Nephrology, Campus Bio Medico University, Rome Italy.
出版信息
J Am Soc Nephrol. 2025 Apr 1;36(4):539-540. doi: 10.1681/ASN.0000000625. Epub 2025 Jan 31.
Abstract
摘要
相似文献
1
Pathogenesis of Organ Damage in Fabry Disease: The AGALopathy Pathogenetic Pathway.法布里病器官损伤的发病机制：α-半乳糖苷酶A缺乏致病途径。
J Am Soc Nephrol. 2025 Apr 1;36(4):539-540. doi: 10.1681/ASN.0000000625. Epub 2025 Jan 31.
2
The Inflammatory Pathogenetic Pathways of Fabry Nephropathy and Agalopathy: GLA Variant Induction of Endoplasmic Reticulum Stress.法布里肾病和无丙种球蛋白血症的炎症致病途径：内质网应激的GLA变异诱导
Nephron. 2025 Feb 20:1-6. doi: 10.1159/000544760.
3
Recent Advances in Understanding the Pathophysiology of Fabry Disease.法布里病病理生理学认识的最新进展
Nephron. 2025 Jun 30:1-3. doi: 10.1159/000546085.
4
Clinical management of female patients with Fabry disease based on expert consensus.基于专家共识的女性法布里病患者的临床管理
Orphanet J Rare Dis. 2025 Jan 7;20(1):7. doi: 10.1186/s13023-024-03500-7.
5
Cognitive dysfunction and depression in Fabry disease: a systematic review.法布里病中的认知功能障碍与抑郁：一项系统综述
J Inherit Metab Dis. 2014 Mar;37(2):177-87. doi: 10.1007/s10545-013-9643-x. Epub 2013 Aug 16.
6
Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.法布里病的酶替代疗法：现有证据的系统评价
Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000.
7
Evolution of Cardiac Damage Staged With Echocardiography in Fabry Disease.法布里病中心脏损害的超声心动图分期演变
J Am Heart Assoc. 2025 Jun 3;14(11):e041627. doi: 10.1161/JAHA.124.041627. Epub 2025 May 23.
8
Fabry-specific treatment in Australia: time to align eligibility criteria with international best practices.在澳大利亚进行特异性 Fabry 治疗：是时候使资格标准与国际最佳实践保持一致了。
Intern Med J. 2024 Jun;54(6):882-890. doi: 10.1111/imj.16327. Epub 2024 Jan 11.
9
Prevalence of Fabry disease in stroke patients--a systematic review and meta-analysis.《脑卒中患者中 Fabry 病的患病率：系统评价和荟萃分析》。
J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):985-92. doi: 10.1016/j.jstrokecerebrovasdis.2013.08.010. Epub 2013 Oct 11.
10
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.法布里病的自然病程及酶替代疗法的有效性：一项系统评价和荟萃分析：酶替代疗法在不同疾病阶段的有效性
J Inherit Metab Dis. 2014 May;37(3):341-52. doi: 10.1007/s10545-014-9677-8. Epub 2014 Feb 4.
引用本文的文献
1
Lysosomal Storage-Independent Fabry Disease Variants with α-Galactosidase A Misprocessing-Induced ER Stress and the Unfolded Protein Response.具有α-半乳糖苷酶A加工错误诱导的内质网应激和未折叠蛋白反应的溶酶体贮积无关型法布里病变体
Nephron. 2025 Mar 20:1-11. doi: 10.1159/000545388.
本文引用的文献
1
Misprocessing of α -Galactosidase A, Endoplasmic Reticulum Stress, and the Unfolded Protein Response.α-半乳糖苷酶A的错误加工、内质网应激与未折叠蛋白反应
J Am Soc Nephrol. 2025 Apr 1;36(4):628-644. doi: 10.1681/ASN.0000000535. Epub 2024 Nov 12.
2
Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis.从阿加糖酶β转换为麦格司他治疗的患者的临床结局：法布瑞登记分析。
J Inherit Metab Dis. 2024 Sep;47(5):1080-1095. doi: 10.1002/jimd.12773. Epub 2024 Jul 4.
3
α-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response.与法布里病相关的α-半乳糖苷酶A错义变体可导致内质网应激并诱导未折叠蛋白反应。
Mol Genet Metab Rep. 2022 Oct 31;33:100926. doi: 10.1016/j.ymgmr.2022.100926. eCollection 2022 Dec.
4
Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease.挑战传统的遗传变异解读方法：法布瑞氏病的启示。
Clin Genet. 2022 Apr;101(4):390-402. doi: 10.1111/cge.14102. Epub 2021 Dec 28.
5
Progress in the understanding and treatment of Fabry disease.法布瑞氏病的研究进展与治疗。
Biochim Biophys Acta Gen Subj. 2020 Jan;1864(1):129437. doi: 10.1016/j.bbagen.2019.129437. Epub 2019 Sep 14.
6
Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy.小分子靶向 TMED9 并促进溶酶体降解以逆转蛋白病。
Cell. 2019 Jul 25;178(3):521-535.e23. doi: 10.1016/j.cell.2019.07.002.
7
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.米加司他治疗法布里病的疗效。
N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.
8
Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.1-脱氧野尻霉素与重组人α-半乳糖苷酶 A 在法布里病患者培养成纤维细胞中的协同作用。
J Inherit Metab Dis. 2012 May;35(3):513-20. doi: 10.1007/s10545-011-9424-3. Epub 2011 Dec 21.
Zotero 插件